OrthoPediatrics (NASDAQ:KIDS) CFO Fred Hite Sells 12,993 Shares of Stock

OrthoPediatrics Corp. (NASDAQ:KIDS) CFO Fred Hite sold 12,993 shares of OrthoPediatrics stock in a transaction on Monday, March 16th. The stock was sold at an average price of $17.25, for a total transaction of $224,129.25. Following the sale, the chief financial officer owned 277,477 shares in the company, valued at $4,786,478.25. This represents a 4.47% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

OrthoPediatrics Price Performance

Shares of KIDS opened at $17.21 on Wednesday. The company has a debt-to-equity ratio of 0.28, a current ratio of 5.55 and a quick ratio of 2.65. OrthoPediatrics Corp. has a 1-year low of $15.28 and a 1-year high of $26.40. The stock has a market cap of $435.07 million, a PE ratio of -10.18 and a beta of 1.07. The firm has a fifty day moving average price of $17.71 and a 200 day moving average price of $17.94.

OrthoPediatrics (NASDAQ:KIDS) last issued its quarterly earnings data on Thursday, February 26th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.11. OrthoPediatrics had a negative return on equity of 6.70% and a negative net margin of 16.77%.The company had revenue of $61.61 million for the quarter, compared to analyst estimates of $61.27 million. As a group, sell-side analysts anticipate that OrthoPediatrics Corp. will post -0.93 EPS for the current year.

Analysts Set New Price Targets

KIDS has been the subject of a number of research reports. BTIG Research boosted their price objective on OrthoPediatrics from $23.00 to $24.00 and gave the company a “buy” rating in a research note on Friday, February 27th. Weiss Ratings restated a “sell (e+)” rating on shares of OrthoPediatrics in a research report on Thursday, January 22nd. Needham & Company LLC lifted their target price on shares of OrthoPediatrics from $26.00 to $30.00 and gave the company a “buy” rating in a report on Friday, February 27th. TD Cowen upgraded shares of OrthoPediatrics to a “strong-buy” rating in a research report on Tuesday, January 27th. Finally, Canaccord Genuity Group initiated coverage on shares of OrthoPediatrics in a research report on Wednesday, December 10th. They set a “buy” rating and a $24.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $24.67.

Trending Headlines about OrthoPediatrics

Here are the key news stories impacting OrthoPediatrics this week:

• Negative Sentiment: CEO David R. Bailey sold 19,535 shares at an average price of $17.25 (≈$336,979); his direct stake fell ~6.15% to 298,020 shares. SEC Filing
• Negative Sentiment: CFO Fred Hite sold 12,993 shares at $17.25 (≈$224,129); his holding decreased ~4.47% to 277,477 shares. SEC Filing
• Negative Sentiment: General Counsel Daniel J. Gerritzen sold 8,614 shares at $17.25 (≈$148,592); his stake fell ~5.45% to 149,533 shares. SEC Filing
• Negative Sentiment: Insider Gregory A. Odle sold 8,433 shares at $17.25 (≈$145,469); his position declined ~4.30% to 187,735 shares. SEC Filing
• Negative Sentiment: Insider Joseph W. Hauser sold 8,596 shares at $17.25 (≈$148,281); his stake fell ~4.23% to 194,767 shares. SEC Filing

Institutional Investors Weigh In On OrthoPediatrics

Large investors have recently modified their holdings of the stock. Millennium Management LLC grew its position in OrthoPediatrics by 48.0% in the 4th quarter. Millennium Management LLC now owns 1,396,495 shares of the company’s stock valued at $24,802,000 after buying an additional 452,840 shares during the last quarter. Prosight Management LP raised its position in OrthoPediatrics by 319.2% during the 3rd quarter. Prosight Management LP now owns 308,707 shares of the company’s stock worth $5,720,000 after buying an additional 235,060 shares during the last quarter. Deerfield Management Company L.P. raised its position in OrthoPediatrics by 1,153.4% during the 3rd quarter. Deerfield Management Company L.P. now owns 194,109 shares of the company’s stock worth $3,597,000 after buying an additional 178,623 shares during the last quarter. Nantahala Capital Management LLC lifted its stake in shares of OrthoPediatrics by 303.3% in the 4th quarter. Nantahala Capital Management LLC now owns 199,449 shares of the company’s stock worth $3,542,000 after acquiring an additional 150,000 shares during the period. Finally, RA Capital Management L.P. acquired a new stake in shares of OrthoPediatrics in the 4th quarter worth $1,953,000. Hedge funds and other institutional investors own 69.05% of the company’s stock.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.